Bryan Giraudo net worth and biography

Bryan Giraudo Biography and Net Worth

CFO of Gossamer Bio
Mr. Giraudo is the Chief Financial Officer of Gossamer Bio. Previously, he was Senior Managing Director at LEERINK Partners, where he was responsible for LEERINK’s Western North America and Asia life sciences investment banking practice. Prior to joining LEERINK Partners in 2009, Bryan was a Managing Director in Merrill Lynch’s Global Healthcare Investment Banking Group. Bryan received his B.A. from Georgetown University.

What is Bryan Giraudo's net worth?

The estimated net worth of Bryan Giraudo is at least $262,165.10 as of July 15th, 2022. Mr. Giraudo owns 20,990 shares of Gossamer Bio stock worth more than $262,165 as of September 28th. This net worth approximation does not reflect any other assets that Mr. Giraudo may own. Additionally, Mr. Giraudo receives an annual salary of $651,800.00 as CFO at Gossamer Bio. Learn More about Bryan Giraudo's net worth.

How old is Bryan Giraudo?

Mr. Giraudo is currently 47 years old. There are 5 older executives and no younger executives at Gossamer Bio. The oldest executive at Gossamer Bio is Mr. Faheem Hasnain, Co-Founder, CEO, Pres & Chairman, who is 64 years old. Learn More on Bryan Giraudo's age.

What is Bryan Giraudo's salary?

As the CFO of Gossamer Bio, Inc., Mr. Giraudo earns $651,800.00 per year. The highest earning executive at Gossamer Bio is Mr. Faheem Hasnain, Co-Founder, CEO, Pres & Chairman, who commands a salary of $895,560.00 per year. Learn More on Bryan Giraudo's salary.

How do I contact Bryan Giraudo?

The corporate mailing address for Mr. Giraudo and other Gossamer Bio executives is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. Gossamer Bio can also be reached via phone at (858) 684-1300 and via email at [email protected] Learn More on Bryan Giraudo's contact information.

Has Bryan Giraudo been buying or selling shares of Gossamer Bio?

During the last ninety days, Bryan Giraudo has bought $99,995.49 in Gossamer Bio stock. Most recently, on Friday, July 15th, Bryan Giraudo bought 13,869 shares of Gossamer Bio stock. The stock was acquired at an average cost of $7.21 per share, with a total value of $99,995.49. Following the completion of the transaction, the chief financial officer now directly owns 20,990 shares of the company's stock, valued at $151,337.90. Learn More on Bryan Giraudo's trading history.

Who are Gossamer Bio's active insiders?

Gossamer Bio's insider roster includes Laura Carter (Insider), Bryan Giraudo (CFO), and Luisa Salter-Cid (Insider). Learn More on Gossamer Bio's active insiders.

Are insiders buying or selling shares of Gossamer Bio?

During the last year, Gossamer Bio insiders bought shares 3 times. They purchased a total of 159,499 shares worth more than $1,149,987.79. During the last year, insiders at the sold shares 8 times. They sold a total of 55,263 shares worth more than $481,644.84. The most recent insider tranaction occured on July, 15th when insider Laura Carter bought 6,934 shares worth more than $49,994.14. Insiders at Gossamer Bio own 8.3 % of the company. Learn More about insider trades at Gossamer Bio.

Information on this page was last updated on 7/15/2022.

Bryan Giraudo Insider Trading History at Gossamer Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/15/2022Buy13,869$7.21$99,995.4920,990View SEC Filing Icon  
3/23/2021Sell5,490$9.48$52,045.20109,889View SEC Filing Icon  
10/14/2020Buy3,000$10.01$30,030.00View SEC Filing Icon  
6/23/2020Buy2,000$12.96$25,920.00View SEC Filing Icon  
5/30/2019Buy1,000$18.70$18,700.00View SEC Filing Icon  
2/12/2019Buy6,000$16.00$96,000.00View SEC Filing Icon  
See Full Table

Bryan Giraudo Buying and Selling Activity at Gossamer Bio

This chart shows Bryan Giraudo's buying and selling at Gossamer Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gossamer Bio Company Overview

Gossamer Bio logo
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $12.49
Low: $12.22
High: $12.66

50 Day Range

MA: $13.24
Low: $11.17
High: $14.88

2 Week Range

Now: $12.49
Low: $5.64
High: $15.19


46,962 shs

Average Volume

1,025,797 shs

Market Capitalization

$1.17 billion

P/E Ratio


Dividend Yield